89bio Corp - ETNB Quarterly EPS earnings growth

89bio Pharma - graphic logo of issuer ETNB

The quarterly earnings per share chart for 89bio, Inc. (ETNB) on GURU.Markets reflects current trends where the metric remains at -47.30, highlighting the company's dependence on external financing and testing stages. However, the development of pegozafermin to combat MASH opens up colossal market prospects. Flawless cold chain performance during drug delivery ensures the stability of all operational processes.

89bio (ETNB) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 11/15/2025

Financial and market metric breakdowns for 89bio, Inc. (ETNB)

- share price and consensus valuation forecast:
Stock Quotes 89bio|ETNB - Analyst Forecast Prices
- issuer market value details:
Market Capitalization 89bio Pharma|ETNB - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share 89bio|ETNB - Company Book Value|Market Value to Book Value Ratio 89bio.com|ETNB - Company Assets
- debt and liquidity data:
Debt to Equity 89bio, Inc.|ETNB - Long-Term Debt to Equity|Short-Term Debt to Capital 89bio Inc|ETNB - Company Total Debt Obligations|Debt to Book Capitalization Ratio 89bio Inc|ETNB - Long-Term Debt Volume|Company Short-Term Debt 89bio|Intermediate Coverage Ratio 89bio.com
- earnings and valuation multiples indicators:
ETNB - Net Financial Result|Projected Future Earnings 89bio, Inc.|ETNB - Price to Earnings Ratio|Forward P/E Multiple 89bio.com|ETNB - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 89bio Corp|ETNB - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months 89bio|ETNB - Earnings per share for the trailing year|Quarterly EPS earnings growth 89bio.com|ETNB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year 89bio, Inc.
- sales volume and revenue information:
ETNB - Company Sales Volume|Projected Sales Volume 89bio Pharma|ETNB - Market Cap to Revenue|Forward Price-to-Revenue Multiple 89bio Inc
Analysis of all company metrics:89bio, Inc.
Manufactured product of 89bio Pharma

Quarterly EPS growth measures the dynamics of net income per share, reflecting the efficiency of business scaling. For 89bio, Inc. (ETNB), this calculation depends directly on the quality of biotechnological logistics and the preservation of drugs during delivery. By analyzing the vector of quarter-over-quarter EPS growth, an investor can see the impact of operating expenses on the bottom line. A stable upward trend confirms the strengthening of the company's market position. Ignoring this trend creates risks of losing investment capital.

Competitors of 89bio, Inc. (ETNB)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|AGIO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months rezolutebio.com (RZLT)|Year-over-year net earnings per share growth for the last 12 months lexpharma.com LXRX|Quarterly EPS earnings growth MBX (MBX Biosciences)|Altimmune Corp - Year-over-year earnings per share growth for the last twelve months|Aardvark Therapeutics Inc. - Quarterly EPS earnings growth|SGMT - Quarterly EPS earnings growth|BioAge Labs (BIOA) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomeafusion.com (BMEA)|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS